ReVance Therapeutics Raises $25 Million

ReVance Therapeutics Inc., a Mountain View, Calif.-based drug developer focused on dermatology and aesthetic medicine, has raised $25.62 million in Series D funding, according to a regulatory filing.

ReVance previously  raised around $64 million in VC funding from Bio*One Capital, Medicis Pharmaceuticals Corp., Essex Woodlands Healthcare Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures and Palo Alto Investors. It also secured $8 million in venture debt funding from Leader Ventures and Horizon Technology Finance.